Jacob A. Ninan, MD

Virginia Cancer Specialists' Physicians

Jacob A. Ninan, MD Headshot

As an oncologist, you develop strong bonds with your patients. At VCS, we are fortunate to have access to state of the art therapies, which allows my patients to get stronger, healthier, and live better lives. My patients have taught me so much about what it means to be a good doctor, and this is what keeps me passionate about what I do every day.

Work and Credentials:

Primary Location


Medical Oncologist

Board Certification

Medical Oncology and Hematology


University of Wisconsin Carbone Comprehensive Cancer Center, Medical Oncology and Hematology


University of Wisconsin

Medical School

University of Michigan Medical School


Northwestern University

Special Interests

Lung cancers, colorectal cancers

Physician Bio

After graduation from the University of Michigan Medical School, Dr. Jacob Ninan completed the internal medicine residency program at the University of Wisconsin. He then spent one year as the primary care chief medical resident at the William S. Middleton Memorial Veterans Hospital in Madison, Wisconsin. Dr. Ninan completed his hematology fellowship at the University of Wisconsin Carbone Comprehensive Cancer Center in 2008 and his oncology fellowship in 2010.

Dr. Ninan has previously done research in bone marrow transplantation and early phase clinical trials. He also has a special interest in hematologic malignancies as well as lung cancers. Dr. Ninan holds memberships in organizations such as the American Society of Clinical Oncology, the American Society of Hematology, and the American Medical Association. Additionally, he serves on hospital-based tumor boards and the Inova Alexandria Hospital Palliative Care Committee.

In addition to dedicated care to his patients, Dr. Ninan is interested in improving international health. In his free time, he enjoys tennis, woodworking, and photography.


Patient Testimonials

Physician Video:


Physician Publications

October 10, 2013

A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors

Read More